William H. Marshall V^1,2,*, Lydia K. Wright²

Congenital Heart Disease, Vol.19, No.4, pp. 419-433, 2024, DOI:10.32604/chd.2024.056608 - 31 October 2024

Abstract Heart failure (HF) is common in patients with congenital heart disease (CHD) and there are limited medical therapies. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a proven medical therapy in patients with acquired HF, though data are limited in patients with CHD. The aim of this review is to summarize the current evidence for use of SGLT2i in patients with CHD and identify future directions for study. In available publications, SGLT2i in patients with CHD seem to be well tolerated, with similar side effect profile to patients with acquired HF. Improvement in functional capacity and natriuretic More >

SHAIL RAKESH MODI, TERRICK ANDEY^*

Oncology Research, Vol.32, No.11, pp. 1709-1721, 2024, DOI:10.32604/or.2024.053972 - 16 October 2024

Abstract Objectives: EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and gefitinib are approved for the treatment of non-small cell lung cancer (NSCLC). However, the high incidence of acquired resistance to these EGFR-TKIs may preclude their effectiveness. Piperlongumine (PPL), an extract from the long pepper fruit (Piper longum), has been shown to possess anticancer properties. The purpose of the study was to investigate piperlongumine as an anticancer agent and to study a combination treatment approach with EGFR-TKIs against lung cancer cells. Methods: Anticancer efficacy of PPL, erlotinib (ERL), gefitinib (GEF), and cisplatin (CIS) were investigated in… More >

FEI CHU¹, KAI TONG¹, XIANG GU¹, MEI BAO¹, YANFEN CHEN¹, BIN WANG², YANHUA SHAO¹, LING WEI^1,*

Oncology Research, Vol.32, No.10, pp. 1661-1671, 2024, DOI:10.32604/or.2024.048287 - 18 September 2024

Abstract Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively More > Graphic Abstract

SIDDAVARAM NAGINI¹, PRATHAP REDDY KALLAMADI², KRANTHI KIRAN KISHORE TANAGALA³, GEEREDDY BHANUPRAKASH REDDY^2,*

Oncology Research, Vol.32, No.8, pp. 1287-1308, 2024, DOI:10.32604/or.2024.049918 - 17 July 2024

Abstract Aldo-keto reductases (AKRs) are a superfamily of enzymes that play crucial roles in various cellular processes, including the metabolism of xenobiotics, steroids, and carbohydrates. A growing body of evidence has unveiled the involvement of AKRs in the development and progression of various cancers. AKRs are aberrantly expressed in a wide range of malignant tumors. Dysregulated expression of AKRs enables the acquisition of hallmark traits of cancer by activating oncogenic signaling pathways and contributing to chemoresistance. AKRs have emerged as promising oncotherapeutic targets given their pivotal role in cancer development and progression. Inhibition of aldose reductase… More >

SNJEŽANA KAŠTELAN^1,2, ANA DIDOVIĆ PAVIČIĆ³, DARIA PAŠALIĆ⁴, TAMARA NIKUŠEVA-MARTIĆ⁵, SAMIR ČANOVIĆ^3,7, PETRA KOVAČEVIĆ^1,6,*, SUZANA KONJEVODA^3,7

Oncology Research, Vol.32, No.8, pp. 1265-1285, 2024, DOI:10.32604/or.2024.048437 - 17 July 2024

Abstract Uveal and conjunctival melanomas are relatively rare tumors; nonetheless, they pose a significant risk of mortality for a large number of affected individuals. The pathogenesis of melanoma at different sites is very similar, however, the prognosis for patients with ocular melanoma remains unfavourable, primarily due to its distinctive genetic profile and tumor microenvironment. Regardless of considerable advances in understanding the genetic characteristics and biological behaviour, the treatment of uveal and conjunctival melanoma remains a formidable challenge. To enhance the prospect of success, collaborative efforts involving medical professionals and researchers in the fields of ocular biology… More > Graphic Abstract

PAULINA CHMIEL^1,2, ALEKSANDRA SłOWIKOWSKA^1,2, ŁUKASZ BANASZEK^1,2, ANNA SZUMERA-CIEćKIEWICZ³, BARTłOMIEJ SZOSTAKOWSKI¹, MATEUSZ J. SPAłEK^1,4,*, TOMASZ ŚWITAJ¹, PIOTR RUTKOWSKI¹, ANNA M. CZARNECKA¹

Oncology Research, Vol.32, No.7, pp. 1141-1162, 2024, DOI:10.32604/or.2024.050350 - 20 June 2024

Abstract Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult… More >

Xiaolu Qin^1,3, Xinyu Li^1,3, Yi Yang², Mei Huang², Shengli Wu¹, Pianchou Gongpan¹, Lianzhang Wu², Juncai He², Changan Geng^1,3,*

Phyton-International Journal of Experimental Botany, Vol.93, No.5, pp. 875-883, 2024, DOI:10.32604/phyton.2024.048192 - 28 May 2024

Abstract The fruits of Amomum tsao-ko (Cao-Guo) were documented in Chinese Pharmacopoeia for the treatment of abdominal pain, vomiting, and plague. In our previous study, a series of diarylheptanes and flavonoids with α-glucosidase and protein tyrosine phosphatase 1B (PTP1B) inhibitory activity have been reported from the middle-polarity part of A. tsao-ko, whereas the antidiabetic potency of the low-polarity constituents is still unclear. In this study, three new hydroxytetradecenals, (2E, 4E, 8Z, 11Z)-6R-hydroxytetradeca-2,4,8,11-tetraenal (1), (2E, 4E, 8Z)-6R-hydroxytetradeca-2,4,8-trienal (2) and (2E, 4E)-6R-hydroxytetradeca-2,4-dienal (3) were obtained from the volatile oils of A. tsao-ko. The structures of compounds 1–3 were determined using spectroscopic data involving 1D and 2D nuclear magnetic More >

SHAHID KARIM^1,*, ALANOUD NAHER ALGHANMI¹, MAHA JAMAL¹, HUDA ALKREATHY¹, ALAM JAMAL², HIND A. ALKHATABI³, MOHAMMED BAZUHAIR¹, AFTAB AHMAD^4,5

Oncology Research, Vol.32, No.5, pp. 817-830, 2024, DOI:10.32604/or.2024.048988 - 23 April 2024

Abstract Cancer frequently develops resistance to the majority of chemotherapy treatments. This study aimed to examine the synergistic cytotoxic and antitumor effects of SGLT2 inhibitors, specifically Canagliflozin (CAN), Dapagliflozin (DAP), Empagliflozin (EMP), and Doxorubicin (DOX), using in vitro experimentation. The precise combination of CAN+DOX has been found to greatly enhance the cytotoxic effects of doxorubicin (DOX) in MCF-7 cells. Interestingly, it was shown that cancer cells exhibit an increased demand for glucose and ATP in order to support their growth. Notably, when these medications were combined with DOX, there was a considerable inhibition of glucose consumption, as More > Graphic Abstract

EFFAT ALEMZADEH¹, LEILA ALLAHQOLI², AFROOZ MAZIDIMORADI³, ESMAT ALEMZADEH^1,4, FAHIMEH GHASEMI^4,5, HAMID SALEHINIYA⁶, IBRAHIM ALKATOUT^7,*

Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006 - 23 April 2024

Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

QIUQIANG CHEN^1,*, XUEJUN GUO², WENXUE MA^3,*

Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383 - 15 November 2023

Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy… More > Graphic Abstract